ArticleAnnals of Indian Academy of Neurology2026
Association of SCN1A and SCN2A Gene Polymorphisms with Antiseizure Medication Responsiveness: A Case-Control Study from Eastern India.
Article in Annals of Indian Academy of Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesEpilepsy, with its complex interplay of neurobiological, genetic, and pharmacological factors, continues to challenge neurologists worldwide-particularly in managing drug resistance. This study aimed to evaluate the frequency of the SCN1A and SCN2A gene polymorphisms among patients with epilepsy (PWE) from Eastern India to assess their relationship with clinical profiles, electroencephalography (EEG) findings, and response to antiseizure medication.
methodsIn this case-control genetic association study, a total of 110 PWE were assessed for demographic and clinical profiles, EEG and neuroimaging findings, and treatment response. SCN1A and SCN2A gene polymorphisms (five selected intronic single nucleotide polymorphisms [SNPs]-four in SCN1A [rs2298771, rs6730344, rs10167228, rs6732655] and one in SCN2A [rs17183814]) were assessed through polymerase chain reaction and restriction fragment length polymorphism.
resultsIn the present study cohort, we observed that the generalized seizure type (73.6%) and early-onset seizures (mean 7.4 years in drug-resistant epilepsy [DRE]) were significantly more frequent in drug-resistant persons. The SCN2A rs17183814 AG genotype frequencies were 36/92 (39.1%) in DRE, 10/18 (55.6%) in responders, and 46/110 (41.8%) in controls. Statistical comparison showed no significant association between the AG genotype and drug resistance (DRE vs. responders: odds ratio [OR] 0.51, 95% confidence interval [CI] 0.19-1.43, P = 0.303; DRE vs. controls: OR 0.89, 95% CI 0.51-1.57, P = 0.808).
conclusionsOn genetic analysis, the AG genotype of SCN2A rs17183814 was numerically higher among responders than DRE, but the difference was not significant. None of the SCN1A SNPs studied ( rs2298771, rs6730344, rs10167228, rs6732655 ) showed significant associations with treatment response, consistent with previous Indian reports.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.